Kazia Therapeutics Ltd ADR (KZIA) Key Statistics & Financial Ratios

Kazia Therapeutics Ltd ADR (KZIA) — Price $10.20 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Kazia Therapeutics Ltd ADR (KZIA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous...

Stock Data

Price$10.20
Market Cap$17M
Beta1.62
ExchangeNASDAQ
CountryAU

Valuation Multiples

P/E Ratio-1.40
Price / Book0.98
P/S1193.49
P/FCF-2.59
Dividend Yield0.00%

Profitability

Gross Margin100.00%
EBIT Margin-92086.45%
EBITDA Margin-92086.45%
Operating Margin-92086.45%
Net Margin-113004.58%

Financial Health

Current Ratio2.87
Quick Ratio2.87
Cash Ratio2.85
Debt / Equity0.00
Debt / Assets0.14%
Interest Coverage0.00
Piotroski F-Score2
Altman Z-Score-40.25

Per-Share Data

Revenue per share0.01
Book Value per share14.88
Cash per share22.24
FCF per share-2.91
Tangible Book Value per share14.53
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy3
Hold0
Sell0
Strong Sell0
Total analysts3
Avg rating (1-5)1.00

Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · OGEN

Explore sector: Healthcare · Biotechnology

More sections of KZIA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks